Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Dr. Joost Breeksema is a Dutch researcher, philosopher, and postdoctoral fellow in the Department of Psychiatry at University Medical Center Groningen (UMCG). He also serves
Missi Wooldridge, Heather Kuiper, Doris Payer, and Logina Mostafa argue that public health has been largely missing from this rapidly evolving landscape, and that 2025 marked an inflection point for “psychedelic public health” as an emerging field.
FDA’s Farchione Says Psychedelic INDs Now “a Third” of Her Workload; NIDA’s Volkow Questions Schedule I Placement • Ipsos/Psychedelic Alpha Poll Probes Americans’ Attitudes Towards Psychedelics • RAND Estimates 10 Million U.S. Adults Microdosed Last Year • Reunion Targets Single Phase 3 Path in PPD; Releases Additional Phase 2 Data • MindMed Rebrands to Definium, Launches LSD Education Push • Interview: Independent Psychedelic Evidence Assessment Working Group • New Jersey Governor Signs $6M Psilocybin Pilot Program Into Law • and more…
We have tracked every investment for the past ten years. Each year, we provide a review of the previous year’s psychedelics fundraising activity, public markets, and M&A. Here, we explore Q4 and full year 2025 via data visualisation and commentary.
Helena Aicher, a researcher and psychotherapist working within Switzerland’s framework for limited medical use, reflects on how Europe’s psychedelics landscape evolved in 2025.
Here, Monica Schweickle, founder of The Psychedelic Consultancy, an Australian firm that supports professionals navigating the country’s psychedelics system, and Psychedelic Alpha Editor Josh Hardman review the progress of the program and explore where it might be headed.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 19, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 12, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 05, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 15, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 8, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 01, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).
Insights and interviews delivered to your inbox. No spam, just valuable information.
